4- Thursday Pharmacotherapy News – 25th March

1 – Countries across Europe suspend use of Oxford-AstraZeneca jab

• UK regulatory agency says vaccine is ‘safe and effective’ despite blood clot fears while WHO urges its continuation
• Countries across Europe have suspended the Oxford/AstraZeneca Covid-19 vaccine over concerns the jab may cause blood clots, even though medicines regulators and the World Health Organization say there is no evidence of problems.
• Germany, Italy, France, Spain and the Netherlands became the latest countries to pause the rollout of the jab on Monday. Norway, Denmark and Bulgaria suspended their programmes last week

Source: Financial Times

2 – Alzheimer’s disease and its treatment by different approaches: A review

• Alzheimer’s disease (AD) is a neurodegenerative disorder that impairs neurocognitive ability.
• Major hypotheses about causes of AD are cholinergic, amyloid, tau hypothesis.
• Diagnostic biomarkers for neurological disorders includes Aβ and tau proteins, Fyn kinases etc.
• Stem cell therapy and nanodrug delivery might be a promising candidate for AD therapeutics.
• In this review, they focus on the causes of the AD and their treatment by different approaches.

Source: ScienceDirect

3 – Improved in vitro and in vivo properties of telmisartan in the co-amorphous system with hydrochlorothiazide: A potential drug-drug interaction mechanism prediction

• Drug-drug co-amorphous systems could be provided with improved solubility, dissolution rate or stability of poorly soluble drugs and may increase therapeutic effect, showing better economic benefits.
• Co-amorphous systems of Telmisartan and Hydrochlorothiazide are reported for the first time, and the combination of Telmisartan and Hydrochlorothiazide is recommended clinically for its increased anti-hypertensive effects and reduced side effects.
• The improved properties of Telmisartan in co-amorphous systems of different molar ratios behaved differently, and all showed improved solubility and dissolution rate compared with crystalline Telmisartan.

Source: ScienceDirect

4- Emerging peptide antibiotics with therapeutic potential

• This review covers some of the recent progress in the field of peptide antibiotics with a focus on compounds with novel or established mode of action and with demonstrated efficacy in animal infection models.
• Novel drug discovery approaches, linear and macrocyclic peptide antibiotics, lipopeptides like the polymyxins as well as peptides addressing targets located in the plasma membrane or in the outer membrane of bacterial cells are discussed.

Source: ScienceDirect

5 – Recent advances in phytochemical-based Nano-formulation for drug-resistant Cancer

• The graph of drug resistance in cancer is reportedly increasing in terms of therapeutic efficiency.
• As per the WHO reports, around 70% of death reported in low- and middle-income countries.
• The 25% increase in disease burden may be laden due to resistance mutations in cancer during treatment.
• The present review highlights the nano-therapeutic approaches pondering over the conventional chemotherapy.

Source: ScienceDirect

6 – Analgesic drug development: proof-of-mechanism and proof-of-concept in early phase clinical studies

• Effective treatment for many pain disorders is still lacking, which is due to the complexity of pain in general and of the underlying pathology of many pain syndromes in particular.
• Here, they describe the top 10 currently most developed analgesic drug classes, link them mechanistically to appropriate methods to demonstrate PoM and PoC in early-phase clinical trials, and include pros and cons of each of the methods described.

Source: ScienceDirect

• Read more from FADIC Blog, with many articles with evidence based articles.
• Learn More Through FADIC® – Online Programs & Mini-Courses.
• Listen Now to FADIC Podcast focusing on varieties of pharmacist perspectives in specialties.
• Read More Now about FADIC Pharmacy Events to get more Experience.

Course Copyrights:

All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.

Why FADIC 2021 Pharmacotherapy Daily News (FNN) ?

• It helps to keep up with the literature!
• Provide you with the Updated with the latest in your clinical practice. Wherever you are, and Whenever you need!
• Help you to share in the advance in clinical career. In addition to adding an impressive image to the pharmacists all-around!

Subscribe to FADIC 2021 Pharmacotherapy Daily News (FNN), for a publication of E-News

Read & Download FNN Issue 8 of April 2020 FNN News